Third Quarter 2023 Financial Results Conference Call Apellis Participants CEDRI C F RANCO I S, M. D. , Ph . D. Co-Founder, President & Chief Executive Officer AD AM TO W NS E ND ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 27-1537290 (State or othe ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q2 2023 Earnings Conference Call July 31, 2023 8:30 AM ET Company Participants Dr. Cedric Francois - Co-Founder and CEO Tim Sullivan - CFO Adam Townsend - CCO Dr. Caroline Baumal - CMO Meredith Kaya - SVP, IR Conference Call Participants Jonathan Miller - Evercore ISI Tazeen Ahmad - Bank of America Anupam Rama - JPMorgan Colleen Kusy - Robert W. Baird Yigal Nochomovitz - Citigroup Steven Seedhouse - Raymond James Phil Nadeau - TD Cowen Justin Kim - Oppenheimer & C ...

Second Quarter 2023 Financial Results Conference Call Apellis Participants CEDRIC F RANCOIS, M.D., Ph.D. Co-Founder, President & Chief Executive Officer ADAM T OWNSEND ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 27-1537290 (State or other jur ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Meredith Kaya - Senior Vice President, Investor Relations and Strategic Finance Dr. Cedric Francois - Co-Founder and CEO Adam Townsend - Chief Commercial Officer Dr. Caroline Baumal - Chief Medical Officer Tim Sullivan - Chief Financial Officer Conference Call Participants Madhu Kumar - Goldman Sachs Jon Miller - Evercore Tazeen Ahmad - BofA Anupam Rama - JPMorgan Colleen Kusy - Baird Yig ...

First Quarter 2023 Financial Results Conference Call May 4, 2023 Apellis Participants C E D R I C F R AN C O I S , M . D . , P h . D . Co-Founder, President & Chief Executive Officer AD A M T O W N S E N D Chief Commercial Officer C AR O L I N E B AU M A L , M . D . Chief Medical Officer T I M O T H Y S U L L I VAN Chief Financial Officer 2 APELLIS PROPRIETARY INFORMATION / FOR APELLIS USE ONLY Forward-looking statements Statements in this presentation about future expectations, plans and prospects, as well ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 27-1537290 (State or other ju ...

Assessment of geographic atrophy progression in the phase 3 OAKS and DERBY trials Allen Chiang, Sujata Sarda, Mark Burch, Min Tsuboi, Daniel Jones, and Ramiro Ribeiro The Association for Research in Vision and Ophthalmology Annual Meeting New Orleans, USA April 23–27, 2023 Phase 3 OAKS and DERBY trials: Design and key criteria Patients with GA secondary to AMD 1258 patients at 232 sites combined Randomized 2:2:1:1 Pegcetacoplan monthly (N=419) Pegcetacoplan EOM (N=420) Sham monthly (N=208) Sham EOM (N=211) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38276 | --- | --- | --- | |----------------------------------------------------------------------------|----------------------------- ...